Abstract
The potential value of glial cell line-derived neurotrophic factor (GDNF) in treating Parkinson's disease (PD) remains controversial. In order to evaluate the therapeutic effect of GDNF-engineered bone marrow stromal cells (BMSCs) in parkinsonian rat model, GDNF-BMSCs and LacZ-BMSCs were transplanted into striatum and followed by Lactacystin lesioning at median forebrain bundles 1 week later. We observed that the intrastriatal transplantation of GDNF-BMSCs could significantly rescue the dopaminergic neurons from lactacystin-induced neurotoxicity with regard to behavioral recovery, tyrosine hydroxylase level in nigra and striatum, and striatal dopamine level. We interpret the outcomes that intrastriatal transplantation of GDNF-BMSCs might be beneficial in the treatment of PD.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acetylcysteine / analogs & derivatives*
-
Acetylcysteine / antagonists & inhibitors
-
Acetylcysteine / toxicity
-
Animals
-
Antimetabolites
-
Apomorphine
-
Behavior, Animal / drug effects
-
Blotting, Western
-
Bone Marrow Transplantation / physiology*
-
Bromodeoxyuridine
-
Cysteine Proteinase Inhibitors / toxicity*
-
Dopamine / metabolism
-
Dopamine Agonists
-
Glial Cell Line-Derived Neurotrophic Factor / genetics
-
Glial Cell Line-Derived Neurotrophic Factor / physiology*
-
Immunohistochemistry
-
Neostriatum / drug effects
-
Neostriatum / metabolism
-
Neostriatum / physiology*
-
Parkinson Disease, Secondary / chemically induced*
-
Parkinson Disease, Secondary / prevention & control*
-
Parkinson Disease, Secondary / psychology
-
Rats
-
Rats, Sprague-Dawley
-
Stereotyped Behavior / drug effects
-
Tissue Engineering
-
Tyrosine 3-Monooxygenase / metabolism
Substances
-
Antimetabolites
-
Cysteine Proteinase Inhibitors
-
Dopamine Agonists
-
Glial Cell Line-Derived Neurotrophic Factor
-
lactacystin
-
Tyrosine 3-Monooxygenase
-
Bromodeoxyuridine
-
Apomorphine
-
Dopamine
-
Acetylcysteine